Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853895 | 1.00 | KDM4E (0.49) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2824939 | 0.89 | KDM4E (0.46) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL257899 | 0.87 | CA12 (0.53) | KDM4EUCHL1CA1CA2HSD17B10 | |
| SCHEMBL29272831 | 0.87 | SMN1; SMN2 (0.48) | KDM4EUCHL1CA1CA2HSD17B10 | |
| SCHEMBL29853503 | 0.86 | KDM4E (0.42) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL27033334 | 0.84 | DGAT1 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3454613 | 0.84 | KDM4E (0.46) | KDM4ECA1CA2HSD17B10GLA | |
| SCHEMBL1717269 | 0.84 | CYP46A1 (0.43) | KDM4EUCHL1NR4A2CA1CA2 | |
| SCHEMBL18107886 | 0.83 | CA12 (0.37) | KDM4EUCHL1CA1CA2HSD17B10 | |
| SCHEMBL19992553 | 0.83 | GAA (0.49) | KDM4EUCHL1CA1CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| US-12286435-B2 | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | BIONNA (BEIJING) MEDICAL TECHNOLOGY CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-05-02 | — | — | US | disclosed |
| EP-3919479-B1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | BIONNA BEIJING MEDICAL TECH CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| WO-2020156357-A1 | COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 博诺康源(北京)药业科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3292124-A2 | FUSED PYRIDINES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | KDM4E 4157/4885CYP1A2 4580/4885CYP2C19 4733/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | KDM4E 1149/4885CYP1A2 4753/4885CYP2C19 4869/4885 |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-12286435-B2 | Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof | BRD4, BRD7, BICRA | KDM4E 717/4885CYP1A2 3192/4885CYP2C19 3056/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | TNNT2, TNNI3, TNNC1 | KDM4E 3913/4885CYP1A2 4808/4885CYP2C19 4876/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | KDM4E 1149/4885CYP1A2 4753/4885CYP2C19 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.